{
    "organizations": [],
    "uuid": "de32733b30e727f41fdc00d90019cb62e5a437a5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bellicum-announces-clinical-hold-l/brief-bellicum-announces-clinical-hold-lifted-on-u-s-studies-of-bpx-501-idUSFWN1RO0YG",
    "ord_in_thread": 0,
    "title": "BRIEF-Bellicum Announces Clinical Hold Lifted On U.S. Studies Of BPX-501",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 11 (Reuters) - Bellicum Pharmaceuticals Inc:\n* BELLICUM ANNOUNCES CLINICAL HOLD LIFTED ON U.S. STUDIES OF BPX-501\n* FDA CLINICAL HOLD DID NOT AFFECT BP-004 REGISTRATIONAL TRIAL IN EUROPE, WHICH IS FULLY ENROLLED\n* LIFT OF CLINICAL HOLD FOLLOWS CONSULTATION WITH FDA & AGREEMENT ON AMENDMENTS TO STUDY PROTOCOLS\n* BELLICUM WILL BE WORKING WITH U.S. CLINICAL SITES TO RESUME PATIENT RECRUITMENT BASED ON AMENDED PROTOCOLS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-12T05:03:00.000+03:00",
    "crawled": "2018-04-12T14:02:09.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "bellicum",
        "pharmaceutical",
        "inc",
        "bellicum",
        "announces",
        "clinical",
        "hold",
        "lifted",
        "study",
        "fda",
        "clinical",
        "hold",
        "affect",
        "registrational",
        "trial",
        "europe",
        "fully",
        "enrolled",
        "lift",
        "clinical",
        "hold",
        "follows",
        "consultation",
        "fda",
        "agreement",
        "amendment",
        "study",
        "protocol",
        "bellicum",
        "working",
        "clinical",
        "site",
        "resume",
        "patient",
        "recruitment",
        "based",
        "amended",
        "protocol",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}